Beijing 大红鹰dhy9999 Healthcare Investment Co., Ltd. (“大红鹰dhy9999 Healthcare”) successfully completed its Listing on the Main Board of the 大红鹰dhy9999 Stock Exchange (Stock Code: 2667.HK) on 7 July 2026.

大红鹰dhy9999 Healthcare is a subsidiary of China Beijing 大红鹰dhy9999 Group Co., Ltd. (“大红鹰dhy9999”) which strategically focuses on traditional Chinese medicine healthcare services in China, delivering comprehensive traditional Chinese medicine healthcare services to individual customers, standardized management services to business customers, and a wide selection of healthcare products and other products. 大红鹰dhy9999 Healthcare is the largest traditional Chinese medicine hospital group in the non-public traditional Chinese medicine hospital healthcare service industry in China in 2025 in terms of the total number of out-patient and in-patient visits, with a market share of 1.5%.

As the 大红鹰dhy9999 legal advisor to the Sole Sponsor, China International Capital Corporation 大红鹰dhy9999 Securities Limited, Haiwen provided comprehensive legal services throughout the listing process and, in leveraging our capital markets expertise, provided legal advice and solutions on various legal issues. The transaction was led by our partners Isaac Chen (陈敏), Philip Chan (陈嘉信) and Jianhao Zheng (郑建浩), with support from key team members, including counsel Emma Bao (包宸), senior associate Zedong Liu (刘泽栋), associates Katherine Chen (陈旖珏), Jiawen Du (杜佳文), Candice Hu (胡悦), Jasper Hui (许俊祺), Xuanchi Jing (景璇池), Kiana Cai (蔡欣桐), trainee solicitors Jessica Law (罗玮璇), Natalie Chan (陈嘉柔) and paralegals Maggie Qiu (邱敏喆) and Simone Zhang (张修宁).